Molbio Diagnostics Limited (NSE:MOLBIO)

India · Delayed Price · Currency is INR

1,322.60

-112.20 (-7.82%)

Oct 21, 2026, 3:29 PM IST

Market Cap	152.42B
Revenue (ttm)	17.54B +109.7%
Net Income	2.49B +144.3%
EPS	22.09 +144.4%
Shares Out	115.24M
PE Ratio	59.87
Forward PE	50.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,605,497
Open	1,463.30
Previous Close	1,434.80
Day's Range	1,307.80 - 1,466.80
52-Week Range	807.00 - 1,686.80
Beta	n/a
Analysts	Strong Buy
Price Target	1,650.00 (+24.75%)
Est. Earnings	Dec 4, 2026

About Molbio Diagnostics

Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2000

Employees 1,225

Stock Exchange National Stock Exchange of India

Ticker Symbol MOLBIO

Full Company Profile

Financial Performance

In fiscal year 2026, Molbio Diagnostics's revenue was 14.46 billion, an increase of 41.68% compared to the previous year's 10.20 billion. Earnings were 1.67 billion, an increase of 14.81%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for MOLBIO stock is "Strong Buy." The 12-month stock price target is ₹1,650, which is an increase of 24.75% from the latest price.

Price Target

₹1,650

(24.75% upside)

Analyst Consensus: Strong Buy

Stock Forecasts